Just One Breath: How Voices of Valley Fever Were Heard Coast to Coast
October 22nd, 2013 8:44 am ET - Blog Administrator
One year ago, valley fever was a disease that few people outside of Arizona or Central California had heard of.
Caused by breathing in spores from a fungus that grows in the dirt throughout the Southwest, coccidioidomycosis – as it is formally known – can cause serious illness and a painful death. It spreads from the lungs to the bones, skin, and organs. It can cause lifelong pain and disability and require years of expensive medications. If you live in one of the 15 states that are required to report cases of the disease to the CDC, you have a greater chance of getting valley fever than you do AIDS, hepatitis, or Lyme disease.
“Is that like yellow fever?” is a typical response.
It might have remained a poorly understood and under-the-radar disease if it weren’t for three things: an intense regional media campaign to focus attention on the disease, a new wave of scientific interest led by the CDC, and the intervention of local and federal policymakers.
Now people throughout the United States know about the disease through big stories in the national media. And two of the top health officials in the country – Dr. Thomas Frieden from the CDC and Dr. Francis Collins from the NIH – have pledged to pull together a multi-million-dollar clinical trial
This all started in the summer of 2012 when ReportingonHealth.org
From Bakersfield to Fresno to Merced to Stockton, the story we heard from editors and reporters was consistent: people in Central California communities had been hit hard by valley fever, but the news outlets had only scratched the surface reporting on it. Over the next year, the Bakersfield Californian, the Merced Sun-Star, Radio Bilingüe in Fresno, The Record in Stockton, Valley Public Radio in Fresno and Bakersfield, Vida en el Valle in Fresno, the Voice of OC in Santa Ana and ReportingonHealth.org banded together under the Reporting On Health Collaborative banner.
Our stories led to coverage by some of the best-read media outlets in the world
At the same time, the CDC began ramping up its publication of journal articles related to valley fever. Between 2000 and 2011, there were an average of two articles on valley fever in CDC publications: MMWR Weekly and Emerging Infectious Diseases. In 2012 alone, though, the CDC published six articles that provided new information about the disease.
Among these studies was one particularly important report. Coccidioidomycosis-associated Deaths, United States, 1990–2008 detailed the mortality from valley fever, the age groups being hit the hardest and the ethnic differences in death rates. Jennifer Y. Huang, Benjamin Bristow, Shira Shafir, and Frank Sorvillo reported:
During 1990–2008, a total of 3,089 coccidioidomycosis-associated deaths among US residents were identified; these deaths represent 55,264 years of potential life lost. The overall crude mortality rate was 0.58 per 1 million person-years (95% CI 0.56–0.61); after age adjustment, the mortality rate was 0.59 deaths per 1 million person-years (95% CI 0.57–0.61).
That report was followed by an update on the upswing in reported valley fever cases in March 2013, in Morbidity and Mortality Weekly Report (MMWR). The study, Increase in Reported Coccidioidomycosis – United States, 1998-2011, was co-authored by two of the CDC’s lead experts in fungal diseases: Dr. Tom Chiller and Dr. Benjamin Park, along with Clarisse A. Tsang, Farzaneh Tabnak, Dr. Duc J. Vugia, and Kaitlin Benedict. They wrote:
This report describes the results of that analysis, which indicated that the incidence of reported coccidioidomycosis increased substantially during this period, from 5.3 per 100,000 population in the endemic area (Arizona, California, Nevada, New Mexico, and Utah) in 1998 to 42.6 per 100,000 in 2011. Health-care providers should be aware of this increasingly common infection when treating persons with influenza-like illness or pneumonia who live in or have traveled to endemic areas.
Within a few weeks of the Just One Breath kickoff in September 2012, Michael Rubio, then a California state senator, called a town hall meeting
“Let’s have a competition: Who can come up with a better test so we can achieve it?” Rubio said to the crowd. “Who can come up with a better treatment so we can have a cost-effective way of treating this very serious disease?”
At the federal level, Sen. Kevin McCarthy, R-Bakersfield, contacted Dr. Frieden at the CDC. McCarthy told reporters earlier this year
“What I would like to do in the short-term is a randomized clinical trial, because no facts are proven out there for the best treatment for valley fever,” he said. “It’s still unknown.”
The unknowns about valley fever are starting to give way to concrete, concerted action. As developments unfold, you can be assured that many more people are going to be paying attention. Gone are the days when valley fever was thought of as an unavoidable risk, the downside of all the upsides of living in the Southwest. People have seen what is possible when the science, policy, and advocacy communities put their heads together, and they want to see that same attention paid to valley fever.
William Heisel


No hay comentarios:
Publicar un comentario